Antigenic relationships between cell membranes of normal and SV40 transformed hamster kidney cells.

Kedar E, Wiener M, Goldblum N, Sulitzeanu D.

Isr J Med Sci. 1971 Jan;7(1):132-43.

Enzymatic enhancement of cell-mediated cytotoxicity and antibody-dependent cell cytotoxicity.

Kedar E, Otiz de Landazuri M, Fahey JL.

J Immunol. 1974 Jan;112(1):26-36.

Cellular immunoadsorbents. An improved technique for specific depletion of cytotoxic (T) lymphoid cells.

Kedar E, Ortiz de Landazuri M, Bonavida B, Fahey JL.

J Immunol Methods. 1974 May;5(1):97-102

In vitro induction of cell-mediated immunity to murine leukemia cells. I. Optimization of tissue culture conditions for the generation of cytotoxic lymphocytes.

Kedar E, Unger E, Schwartzbach M.

J Immunol Methods. 1976;13(1):1-19.

Natural cell-mediated cytotoxicity in vitro and inhibition of tumor growth in vivo by murine lymphoid cells cultured with T cell growth factor (TCGF).

Kedar E, Ikejiri BL, Gorelik E, Herbermann RB.

Cancer Immunol Immunother. 1982;13(1):14-23.

The in vitro generation of effector lymphocytes and their employment in tumor immunotherapy.

Kedar E, Weiss DW.

Adv Cancer Res. 1983;38:171-287. Review.

Immunotherapy of murine and human tumors in mice with lymphokines and interleukin-2-propagated lymphocytes.

Kedar E, Chriqui-Zeira E, Kyriazis AP.

J Biol Response Mod. 1984 Oct;3(5):517-26.

Therapy of advanced solid tumors in mice using chemotherapy in combination with interleukin-2 with and without lymphokine-activated killer cells.

Kedar E, Ben-Aziz R, Shiloni E.

Isr J Med Sci. 1988 Sep-Oct;24(9-10):494-504.

Cancer immunotherapy: are the results discouraging? Can they be improved?

Kedar E, Klein E.

Adv Cancer Res. 1992;59:245-322. Review

Chemo-immunotherapy of murine solid tumors: enhanced therapeutic effects by interleukin-2 combined with interferon alpha and the role of specific T cells.

Kedar E, Rutkowski Y, Leshem B.

Cancer Immunol Immunother. 1992;35(1):63-8.

Chemo-immunotherapy in patients with metastatic melanoma using sequential treatment with dacarbazine and recombinant human interleukin-2: evaluation of hematologic and immunologic parameters and correlation with clinical response.

Isacson R, Kedar E, Barak V, Gazit Z, Yurim O, Kalichman I, Ben-Bassat H, Biran S, Schlesinger M, Franks CR, et al.

Immunol Lett. 1992 Jul;33(2):127-34.

Delivery of cytokines by liposomes. II. Interleukin-2 encapsulated in long-circulating sterically stabilized liposomes: immunomodulatory and anti-tumor activity in mice.

Kedar E, Braun E, Rutkowski Y, Emanuel N, Barenholz Y.

J Immunother Emphasis Tumor Immunol. 1994 Aug;16(2):115-24.

Targeted delivery of doxorubicin via sterically stabilized immunoliposomes: pharmacokinetics and biodistribution in tumor-bearing mice.

Emanuel N, Kedar E, Bolotin EM, Smorodinsky NI, Barenholz Y.

Pharm Res. 1996 Jun;13(6):861-8.

Enhancement of antitumor activity of polyethylene glycol-coated liposomal doxorubicin with soluble and liposomal interleukin 2.

Cabanes A, Even-Chen S, Zimberoff J, Barenholz Y, Kedar E, Gabizon A.

Clin Cancer Res. 1999 Mar;5(3):687-93.

A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. I. Vaccine characterization and efficacy studies in mice.

Babai I, Samira S, Barenholz Y, Zakay-Rones Z, Kedar E.

Vaccine. 1999 Mar 5;17(9-10):1223-38.

Immunoadjuvant activity of interferon-gamma-liposomes co-administered with influenza vaccines.

van Slooten ML, Hayon I, Babai I, Zakay-Rones Z, Wagner E, Storm G, Kedar E.

Biochim Biophys Acta. 2001 Mar 30;1531(1-2):99-110.

A novel liposomal influenza vaccine (INFLUSOME-VAC) containing hemagglutinin-neuraminidase and IL-2 or GM-CSF induces protective anti-neuraminidase antibodies cross-reacting with a wide spectrum of influenza A viral strains.

Babai I, Barenholz Y, Zakay-Rones Z, Greenbaum E, Samira S, Hayon I, Rochman M, Kedar E.

Vaccine. 2001 Nov 12;20(3-4):505-15.

Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME-VAC) in young adults.

Ben-Yehuda A, Joseph A, Zeira E, Even-Chen S, Louria-Hayon I, Babai I, Zakay-Rones Z, Greenbaum E, Barenholz Y, Kedar E.

J Med Virol. 2003 Apr;69(4):560-7.

Immunogenicity and safety of a novel IL-2-supplemented liposomal influenza vaccine (INFLUSOME-VAC) in nursing-home residents.

Ben-Yehuda A, Joseph A, Barenholz Y, Zeira E, Even-Chen S, Louria-Hayon I, Babai I, Zakay-Rones Z, Greenbaum E, Galprin I, Glück R, Zurbriggen R, Kedar E.

Vaccine. 2003 Jul 4;21(23):3169-78.

A new intranasal influenza vaccine based on a novel polycationic lipid–ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.

Joseph A, Itskovitz-Cooper N, Samira S, Flasterstein O, Eliyahu H, Simberg D, Goldwaser I, Barenholz Y, Kedar E.

Vaccine. 2006 May 1;24(18):3990-4006.

Adjuvanted influenza vaccines.

Even-Or O, Samira S, Ellis R, Kedar E, Barenholz Y.

Expert Rev Vaccines. 2013 Sep;12(9):1095-108.